Beyond The Printed Page

  1. How Might Biopharma Manufacturing Differ In The Next Decade?
    5/23/2018

    Three biopharmaceutical key opinion leaders envision the future of manufacturing in 2028 and beyond.

  2. More Questions About Regeneron’s Approach To Blue-Sky Research
    5/21/2018

    George Yancopoulos, M.D., Ph.D., president and chief scientific officer at Regeneron Pharmaceuticals, shares thoughts on “blue sky” research, and the important role it plays in remaining a productive R&D innovation engine.

  3. Emerging Innovations — And Their Pending Impact On Biopharma Manufacturing
    5/17/2018

    Three biopharmaceutical manufacturing executives provide perspective on what emerging innovations could impact manufacturing within the next few years.

  4. 6 Manufacturing KOLs Reveal The Trends They Find Most Exciting
    5/15/2018

    Six biopharmaceutical industry key opinion leaders reveal what manufacturing trends they find most exciting and why. 

  5. 3 Questions With Regeneron’s Chief Scientific Officer — George Yancopoulos
    5/14/2018

    George Yancopoulos, M.D., Ph.D., president and chief scientific officer at Regeneron Pharmaceuticals, discusses failure, finding top talent, and thoughts on retirement.  

  6. What Transformative Technologies Are Biopharma Manufacturing Leaders Watching?
    5/9/2018

    Five biopharma manufacturing leaders share their thoughts on the disruptive technologies with the potential to transform biopharmaceutical industry manufacturing.

  7. Preparing For JPM As A Small Private Company
    4/30/2018

    Michael Bonney shares what it was like to prepare (somewhat last minute) and present at the annual J.P. Morgan Healthcare Conference (JPM) as the CEO of Kaleido Biosciences, a small privately-held biopharmaceutical company. In addition, he compares this to previous experiences of presenting at JPM as the CEO of a larger publically traded biopharma.

  8. Michael Bonney On How Biogen And Cubist Differ From Kaleido Biosciences
    4/23/2018

    Michael Bonney, CEO of Kaleido Biosciences, discusses some of the differences between his past and present employers.

  9. Achieving Leadership Diversity Isn’t Easy
    4/16/2018

    Michael Bonney, CEO of Kaleido Biosciences, discusses some of the challenges faced — and how to overcome those — when building a diverse leadership team.

  10. 4 Questions With John Maraganore, CEO Of Alnylam Pharmaceuticals
    3/19/2018

    John Maraganore, CEO of Alnylam Pharmaceuticals and current chair for BIO, shares thoughts on CROs, open science, and his company’s future.